Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

被引:6
|
作者
Sinari, Shripad [1 ]
Koska, Juraj [2 ,9 ]
Hu, Yueming [3 ]
Furtado, Jeremy [4 ]
Jensen, Majken K. [4 ,5 ]
Budoff, Matthew J. [6 ]
Nedelkov, Dobrin [3 ]
McClelland, Robyn L. [7 ]
Billheimer, Dean [1 ]
Reaven, Peter [8 ]
机构
[1] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA
[2] Phoenix VA Hlth Care Syst, Phoenix, AZ USA
[3] Isoformix Inc, Phoenix, AZ USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[5] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark
[6] Harbor Univ Calif Los Angeles UCLA, Lundquist Inst, Torrance, CA USA
[7] Univ Washington, Dept Biostat, Seattle, WA USA
[8] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA
[9] Phoenix VA Hlth Care Syst, 650 E Indian Sch Rd CS111E, Phoenix, AZ 85012 USA
关键词
apolipoprotein; cardiovascular disease; lipids; risk; APOLIPOPROTEIN-C-III; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; SIALIC-ACID; ASSOCIATION; INHIBITION; ATHEROSCLEROSIS; POLYMORPHISM; CHOLESTEROL; EXPRESSION;
D O I
10.1161/ATVBAHA.123.319035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Apo CIII (apolipoprotein CIII) is an important regulator of triglyceride metabolism and was associated with cardiovascular risk in several cohorts. It is present in 4 major proteoforms, a native peptide (CIII0a), and glycosylated proteoforms with zero (CIII0b), 1 (CIII1, most abundant), or 2 (CIII2) sialic acids, which may differentially modify lipoprotein metabolism. We studied the relationships of these proteoforms with plasma lipids and cardiovascular risk. Methods:Apo CIII proteoforms were measured by mass spectrometry immunoassay in baseline plasma samples of 5791 participants of Multi-Ethnic Study of Atherosclerosis, an observational community-based cohort. Standard plasma lipids were collected for up to 16 years and cardiovascular events (myocardial infarction, resuscitated cardiac arrest, or stroke) were adjudicated for up to 17 years. Results:Apo CIII proteoform composition differed by age, sex, race and ethnicity, body mass index, and fasting glucose. Notably, CIII1 was lower in older participants, men and Black and Chinese (versus White) participants, and higher in obesity and diabetes. In contrast, CIII2 was higher in older participants, men, Black, and Chinese persons, and lower in Hispanic individuals and obesity. Higher CIII2 to CIII1 ratio (CIII2/III1) was associated with lower triglycerides and higher HDL (high-density lipoprotein) in cross-sectional and longitudinal models, independently of clinical and demographic risk factors and total apo CIII. The associations of CIII0a/III1 and CIII0b/III1 with plasma lipids were weaker and varied through cross-sectional and longitudinal analyses. Total apo CIII and CIII2/III1 were positively associated with cardiovascular disease risk (n=669 events, hazard ratios, 1.14 [95% CI, 1.04-1.25] and 1.21 [1.11-1.31], respectively); however, the associations were attenuated after adjustment for clinical and demographic characteristics (1.07 [0.98-1.16]; 1.07 [0.97-1.17]). In contrast, CIII0b/III1 was inversely associated with cardiovascular disease risk even after full adjustment including plasma lipids (0.86 [0.79-0.93]). Conclusions:Our data indicate differences in clinical and demographic relationships of apo CIII proteoforms, and highlight the importance of apo CIII proteoform composition in predicting future lipid patterns and cardiovascular disease risk.
引用
收藏
页码:1560 / 1571
页数:12
相关论文
共 50 条
  • [1] Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies
    Soto, Lorenzo G. de la Parra
    Gutierrez-Uribe, Janet A.
    Sharma, Ashutosh
    Ramirez-Jimenez, Aurea K.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (02) : 295 - 308
  • [2] Lipids and Cardiovascular Risk with CKD
    Afshinnia, Farsad
    Pennathur, Subramaniam
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (01): : 5 - 7
  • [3] Optimization of time interval for the measurement of plasma lipids for cardiovascular disease risk assessment
    Sampson, Maureen
    Wolska, Anna
    Zubiran, Rafael
    Cole, Justine
    Amar, Marcelo
    Remaley, Alan T.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2024, 24 (1-2) : 123 - 133
  • [4] Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids
    Naber, Annemieke
    Demus, Daniel
    Slieker, Roderick
    Nicolardi, Simone
    Beulens, Joline W. J.
    Elders, Petra J. M.
    Lieverse, Aloysius G.
    Sijbrands, Eric J. G.
    Hart, Leen M. 't
    Wuhrer, Manfred
    van Hoek, Mandy
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [5] Haplotype analysis of Apo AI-CIII-AIV gene cluster and lipids level: Tehran lipid and glucose study
    Daneshpour, Maryam S.
    Faam, Bita
    Mansournia, Mohamad Ali
    Hedayati, Mehdi
    Halalkhor, Sohrab
    Mesbah-Namin, Seyed Alireza
    Shojaei, Shahla
    Zarkesh, Maryam
    Azizi, Fereidoun
    ENDOCRINE, 2012, 41 (01) : 103 - 110
  • [6] Plasma lipids and cardiovascular risk: a POSCH report
    Buchwald, H
    Boen, JR
    Nguyen, PA
    Williams, SE
    Matts, JP
    ATHEROSCLEROSIS, 2001, 154 (01) : 221 - 227
  • [7] The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
    von Ballmoos, Moritz C. Wyler
    Haring, Bernhard
    Sacks, Frank M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (04) : 498 - 510
  • [8] Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis
    Koska, Juraj
    Furtado, Jeremy
    Hu, Yueming
    Sinari, Shripad
    Budoff, Matthew J.
    Billheimer, Dean
    Nedelkov, Dobrin
    McClelland, Robyn L.
    Reaven, Peter D.
    JOURNAL OF LIPID RESEARCH, 2022, 63 (09)
  • [9] Resveratrol: Effects on Lipids and Cardiovascular Risk
    Cherniack E.P.
    Troen B.R.
    Current Cardiovascular Risk Reports, 2013, 7 (1) : 9 - 16
  • [10] Cardiovascular Risk, Lipids and Pregnancy: Preeclampsia and the Risk of Later Life Cardiovascular Disease
    Charlton, Francesca
    Tooher, Jane
    Rye, Kerry-Anne
    Hennessy, Annemarie
    HEART LUNG AND CIRCULATION, 2014, 23 (03) : 203 - 212